By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, ...
Hosted on MSN
FDA delays full approval of Novavax COVID-19 vaccine even though it was on track for clearance
The U.S. Food and Drug Administration has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results